Medicare drug coverage

Xigduo: 2027 Medicare Part D coverage

2,360 of 5,495 Part D plans (43%) list Xigduo on their 2027 formulary, down 51 points from 2026. 99% of those require prior authorization, step therapy, or a quantity limit.

License. US government work, Public Domain Mark 1.0.

2027 compared with 2026

Xigduo is number 191 by total Medicare Part D spending in 2024 ($204 million). Plans that list it most often put it on tier 3. Counts use 6 RxNorm products for this name.

Xigduo Part D coverage, 2026 and 2027
Measure20262027Change
Part D plans in the file5,5185,495-23
Plans that list it5,163 (94%)2,360 (43%)-51 points
Prior authorization (of plans that list it)0 (0%)0 (0%)no change
Step therapy (of plans that list it)1 (0%)0 (0%)no change
Quantity limit (of plans that list it)5,027 (97%)2,348 (99%)+2 points
Any of the three (of plans that list it)5,027 (97%)2,348 (99%)+2 points
Not listed or restricted (of all plans)5,382 (98%)5,483 (100%)+2 points

Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page

Source: CMS 2026 Part D formulary file (basic drugs and plan information), as of September 30, 2026. Publisher page

Formulary tier

Xigduo formulary tier, 2026 and 2027
Tier2026 plans2027 plans
Tier 1160 (3%)34 (1%)
Tier 29 (0%)268 (11%)
Tier 34,962 (96%)2,050 (87%)
Tier 632 (1%)8 (0%)

Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page

Source: CMS 2026 Part D formulary file (basic drugs and plan information), as of September 30, 2026. Publisher page

Plan by plan, 2026 to 2027

4,380 plan ids are in both files. 80 of them (2%) added prior authorization, step therapy, or a quantity limit for Xigduo, and 2,098 stopped listing it.

Xigduo: plans in both 2026 and 2027
Plan by planPlans
Same plan id in both years4,380
Listed it in 2026, not in 20272,098 (48%)
Listed it in 2027, not in 20260 (0%)
Moved it to a higher tier9 (0%)
Added prior authorization0 (0%)
Added step therapy0 (0%)
Added a quantity limit80 (2%)
Added at least one of the three80 (2%)
Removed at least one of the three1 (0%)
Plan ids new in 20271,115
2026 plan ids not in the 2027 file1,138

Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page

Source: CMS 2026 Part D formulary file (basic drugs and plan information), as of September 30, 2026. Publisher page

States from most to least restrictive

Share of 2027 Part D plans offered in each state that leave Xigduo off the formulary or list it with prior authorization, step therapy, or a quantity limit. Alaska ranks first at 100%, with 0% of its plans using prior authorization or step therapy; Massachusetts ranks last at 87%. Ties break on the prior authorization or step therapy share.

States from most to least restrictive for Xigduo, 2027
RankState2027 plansNot listed or restrictedPrior auth or step therapyChange from 2026
1Alaska9100%0%no change
2Alabama115100%0%no change
3Arkansas86100%0%no change
4Arizona148100%0%+4 points
5California397100%0%no change
6Colorado106100%0%no change
7Connecticut54100%0%+4 points
8District of Columbia21100%0%no change
9Delaware43100%0%no change
10Florida549100%0%+3 points
11Georgia151100%0%no change
12Hawaii50100%0%+4 points
13Iowa64100%0%+12 points
14Idaho45100%0%no change
15Illinois133100%0%+1 point
16Indiana140100%0%+2 points
17Kansas84100%0%no change
18Kentucky123100%0%+1 point
19Louisiana126100%0%no change
20Maryland49100%0%+5 points
21Maine52100%0%no change
22Michigan183100%0%no change
23Minnesota63100%0%+7 points
24Missouri171100%0%+2 points
25Mississippi105100%0%no change
26Montana27100%0%no change
27North Carolina177100%0%+4 points
28North Dakota26100%0%+15 points
29Nebraska51100%0%+7 points
30New Hampshire25100%0%no change
31New Jersey74100%0%no change
32New Mexico68100%0%no change
33Nevada100100%0%+5 points
34New York215100%0%+3 points
35Ohio173100%0%no change
36Oklahoma81100%0%no change
37Oregon92100%0%no change
38Pennsylvania324100%0%+1 point
39Rhode Island29100%0%no change
40South Carolina91100%0%+8 points
41South Dakota30100%0%+13 points
42Tennessee157100%0%no change
43Texas412100%0%+1 point
44Utah53100%0%no change
45Virginia145100%0%no change
46Vermont14100%0%no change
47Washington114100%0%no change
48Wisconsin97100%0%+14 points
49West Virginia70100%0%no change
50Wyoming13100%0%no change
51Massachusetts9287%0%+21 points

Source: CMS CY2027 landscape file (states and parent organizations), as of September 30, 2026. Publisher page

Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page

By parent organization

164 parent organizations offer 2027 Part D plans. Humana Inc. has the most, 884, and 100% of them leave Xigduo off or restrict it.

Xigduo coverage by parent organization, 2027
Parent organization2027 plans ↓List itRestrict it (of listing)Not listed or restrictedChange from 2026Plans that added a restriction
Humana Inc.8840%none list it100%no change0
UnitedHealth Group, Inc.850100%100%100%no change2
Devoted Health, Inc.7280%none list it100%no change0
CVS Health Corporation633100%100%100%no change0
Elevance Health, Inc.2940%none list it100%no change0
Centene Corporation268100%100%100%no change0
Health Care Service Corporation2312%100%100%no change0
Kaiser Foundation Health Plan, Inc.1120%none list it100%no change0
Highmark Health9893%100%100%no change0
SCAN Group850%none list it100%no change0
Alignment Healthcare USA, LLC770%none list it100%no change0
Guidewell Mutual Holding Corporation55100%100%100%no change0
Blue Cross Blue Shield of Michigan Mutual Ins. Co.43100%100%100%no change0
Molina Healthcare, Inc.430%none list it100%no change0
Corewell Health400%none list it100%no change0
Zing Health Consolidator, Inc360%none list it100%no change0
CAPITAL BLUE CROSS3523%100%100%no change0
Medica Holding Company310%none list it100%no change0
UPMC Health System300%none list it100%no change0
Universal Health Services, Inc.29100%100%100%no change0
MHH Healthcare, L.P.260%none list it100%no change0
Independence Health Group, Inc.25100%100%100%no change0
Point32Health, Inc.23100%100%100%+100 points19
BlueCross BlueShield of Tennessee220%none list it100%no change0
California Physicians' Service22100%100%100%no change0

Source: CMS CY2027 landscape file (states and parent organizations), as of September 30, 2026. Publisher page

Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page

Run it in Rivvi

Which 2027 plans near you dropped or restricted Xigduo?

Tier changes and new prior auth, step therapy or quantity limits, plan by plan, before open enrollment.

Free to start. Opens Rivvi, the AI workspace for healthcare teams.

Near it by Part D spending

About this data

A plan here is one Part D plan as the CMS formulary files list it: contract, plan, and segment. That covers Medicare Advantage plans with drug coverage and stand-alone drug plans. A plan lists a drug when its formulary has a row for any RxNorm product of that name. When it has several, the row with the lowest tier is the one counted, and restricted means that row has prior authorization, step therapy, or a quantity limit.

A plan with no row for the drug counts as not listing it. That can be a product the file codes another way, so read a low count as a lookup result, not a coverage decision. A state counts every plan the CMS landscape file offers there. Parent organizations are named as CMS names them. The drug list is the top 200 by total Part D spending.

Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page

Source: CMS CY2027 landscape file (states and parent organizations), as of September 30, 2026. Publisher page

Source: CMS Medicare Part D Spending by Drug, 2024 data, as of June 25, 2026. Publisher page

Try it on your own data today.

Free to start. Most teams are using it the same day.

Get started for freeSee pricing